Endo (ENDP) Tops Q3 EPS by 3c, Affirms FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Endo (ENDP) Tops Q3 EPS by 3c, Affirms FY Guidance

Endo Reports Third Quarter 2015 Financial Results

November 5, 2015 6:30 AM EST

DUBLIN, Nov. 5, 2015 /PRNewswire/ --

Third quarter revenues of $746 million, a 14 percent increase from third quarter of 2014 Third quarter reported $3.84 diluted (GAAP) loss per share from continuing operations and $1.02 adjusted diluted EPS from continuing operations U.S. Branded Pharmaceuticals third quarter revenue increase of 27 percent primarily attributable to the acquisition of Auxilium Pharmaceuticals U.S. Generic Pharmaceuticals continues strong growth in third quarter with 15 percent revenue increase over third quarter 2014 International Pharmaceuticals third quarter results on-track and aligned with Company... More